Intelligent Bio Solutions Q2 net loss narrows to $0.42M; govt support income up 52%

INTELLIGENT BIO SOLUTIONS INC.

2024-Q2 EPS reported -$23.65 vs consensus -$5.20 ▼ miss (-354.6%)

Net loss of $0.42M ($0.46/shr) vs $3.46M ($4.65/shr) in prior year period.
Government support income rose 52% to $269,625 on R&D qualifying expenditures.
Cash and equivalents $2.9M at quarter-end; successful completion of Milestone 7 biosensor phase.
Milestone 7 achieved 4x improvement in time-to-result, enabling under-one-minute test.
Partnered with Boughey Distribution and Hozelock for fingerprint drug testing programs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTELLIGENT BIO SOLUTIONS INC. reported fiscal second quarter ended December 31, 2022 results: net income $0.42 million or $0.46 per share, EPS $0.46 per share.

Period: fiscal second quarter ended December 31, 2022
Net income: $0.42 million or $0.46 per share
EPS: $0.46 per share
Result: reported results

Exact text from the filing

For the quarter that ended December 31, 2022, the Company had a net loss of $0.42 million or $0.46 per share

View on SEC.gov

Browse all earnings releases →

INTELLIGENT BIO SOLUTIONS INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-005216

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.